Roche will pay a purchase price of USD 2.7B upfront to acquire Carmot Therapeutics

Basel, Switzerland, December 4, 2023 (Globe Newswire) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced its definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as several preclinical programs. Carmot Therapeutics’s R&D portfolio of clinical stage incretins has significant potential to treat obesity, diabetes, and potentially other diseases, both as standalone medicines and in combination with Roche’s in-house assets. According to the agreement's terms, Roche will pay a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 million.

Read full article here.